KBL Merger Corp IV (KBLMU)

$ 8.38
-3.18 (-27.51%)
-
Symbol KBLMU
Price $ 8.38
Beta -0.022
Volume Avg. 0.00M
Market Cap 0.04B
Shares () -
52 Week Range 7.62-14.52
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -17.65% Sell
ROA -22.50% Sell
Operating Margin -
Debt / Equity 38.31% Neutral
P/E -12.85 Strong Sell
P/B 4.11 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

In Pursuit of the Elusive Drug — the Billion-Dollar Blockbuster - NetworkNewsWire

In Pursuit of the Elusive Drug — the Billion-Dollar Blockbuster - NetworkNewsWire

NetworkNewsWire Editorial Coverage: Enormous amounts of money exchange hands in the big pharma space as companies merge and are acquired — all in search of the next blockbuster drug. While the discovery of a blockbuster drug, or a drug that generates... ...

https://www.networknewswire.com
Banking on the Next Blockbuster Drug - NetworkNewsWire

Banking on the Next Blockbuster Drug - NetworkNewsWire

NetworkNewsWire Editorial Coverage: Pharmaceutical companies invest enormous amounts of time and money on the research and development of new drugs, typically years in the making and costing millions of dollars. Only occasionally is a new drug develo... ...

https://www.networknewswire.com
180 Life Sciences Corp. Expands IP Portfolio with EU, U.S., and Chinese Patents - NetworkNewsWire

180 Life Sciences Corp. Expands IP Portfolio with EU, U.S., and Chinese Patents - NetworkNewsWire

The company’s patent portfolio includes its own intellectual property and exclusive worldwide licenses, including in the U.S., Canada, Europe, Australia, Hong Kong, and China 180 Life Sciences is in the final stages of its merger process with KBL Mer... ...

https://www.networknewswire.com
SPACs Surge as Biotech Booms - NetworkNewsWire

SPACs Surge as Biotech Booms - NetworkNewsWire

NetworkNewsWire Editorial Coverage: As the world has focused on the search for COVID vaccines and therapeutics, biotech IPOs have quietly gone bonkers. As a matter of fact, 2020 is on track to post the highest number of biotech IPOs in over five year... ...

https://www.networknewswire.com
Blockbuster Year and Bright Horizons for SPACs - NetworkNewsWire

Blockbuster Year and Bright Horizons for SPACs - NetworkNewsWire

NetworkNewsWire Editorial Coverage: The year 2020 has already seen 127 SPAC IPOs, which have collectively raised over $48.5 billion in proceeds — more than the past ten years combined. A special purpose acquisition company (SPAC) is essentially a bla... ...

https://www.networknewswire.com
Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation - NetworkNewsWire

Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation - NetworkNewsWire

NetworkNewsWire Editorial Coverage: Innovation and breakthroughs in the biotech industry are essential to identifying and providing life-saving treatments. Companies that invest substantial amounts of time, effort, and resources in key areas of resea... ...

https://www.networknewswire.com
Solving One of the Largest Drivers of Disease: Inflammation - NetworkNewsWire

Solving One of the Largest Drivers of Disease: Inflammation - NetworkNewsWire

NetworkNewsWire Editorial Coverage: Inflammation typically occurs in the body as a natural response to threats such as infection or injury, but chronic inflammation can cause severe damage and even death. Inflammation is a well-known symptom of multi... ...

https://www.networknewswire.com
KBL Merger Corp. IV (NASDAQ: KBLM) Fulfilling IPO Goal Through Merger With 180 Life Sciences Corp. - NetworkNewsWire

KBL Merger Corp. IV (NASDAQ: KBLM) Fulfilling IPO Goal Through Merger With 180 Life Sciences Corp. -...

KBL Merger Corp. IV is set to finalize the acquisition of 180 Life Sciences Corp. during Q4 2020 180 Life Sciences Corp. has several ongoing programs at different stages of development, with the leading candidate in Phase 2b/3, helping mitigate the r... ...

https://www.networknewswire.com
Sebi pulls up Kirloskar’s promoters for fraud

Sebi pulls up Kirloskar’s promoters for fraud

In a showcause notice to the six promoters of KBL and two others, Sebi alleged that the promoter group was aware of the precarious financial condition of KBL when these shares were sold, committing a fraud on minority shareholders of Kirloskar Indust... ...

https://www.hindustantimes.com
3 SPACs Score - CCXX, SPAQ, & HYAC

3 SPACs Score - CCXX, SPAQ, & HYAC

SPAC Winners And Losers. SPAC Size Matters. ...

seekingalpha.com

About


Dr. Marlene Krauss
Financial Services
Shell Companies
Nasdaq Capital Market

KBL Merger Corp. IV. is a blank check company. The Company is formed for the purpose of effecting merger, capital stock exchange, stock purchase, asset acquisition or other similar business combination with one or more operating businesses. The Company intend to focus on acquiring an operating company in the healthcare and related wellness industry. The Company has not generated any revenue.